CAMPATH®

(Alemtuzumab)

Documentation

Patented
Approved 2001
FDA Letter
FDA Label
Full Sequence

Brief Summary

Function Type: ADCC
Target: CD52
Indication Category: Autoimmunity

Approved Indications

Detailed Summary

Side Effects

References

Wikipedia
Drugs.com
FDA